Maynard Um
-
-
-
-
-
-
-
Genflow Biosciences PLC Announces Directorate Change
-
-
-
-
-
-
-
Editas Medicine (EDIT) PT Raised to $4 at Wells Fargo
-
-
-
-
-
-
-
Editas Medicine (EDIT) Misses Q1 EPS by 36c
-
-
-
-
-
-
-
Editas Medicine (EDIT) Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities
-
-
-
-
-
-
-
Truist Securities Downgrades Editas Medicine (EDIT) to Hold
-
-
-
-
-
-
-
Oppenheimer Reiterates Perform Rating on Editas Medicine (EDIT)
-
-
-
-
-
-
-
Editas Medicine (EDIT) Announces Progress Towards 2024 Goals, Including Achievement of In Vivo Preclinical Proof of Concept and Strategic Update
-
404,872 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

